Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Preparing for Semaglutide Microdosing to Maintain Cardiovascular Health in People with HIV: The (pre-)SMASH CVD Trial

Award Number: R34HL182386
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/15/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Preparing for Semaglutide Microdosing to Maintain Cardiovascular Health in People with HIV: The (pre-)SMASH CVD Trial - PROJECT SUMMARY Cardiometabolic diseases are leading causes of non-AIDS-related morbidity and mortality among people living with HIV (PWH). Obesity, a global epidemic, further increases cardiometabolic disease risk. Long-acting glucagon-like peptide-1 receptor agonists (GLP-1RA) promote clinically significant weight loss and reduction of cardiometabolic risk in adults with and without HIV. Problematically: there are no established strategies to maintain therapeutic benefits of GLP-1RA except for continued, full-dose therapy; lifelong, high-dose GLP-1RA therapy is impractical, costly and may have yet unknown risks; and drug cessation is associated with rapid weight regain and loss of cardiometabolic benefit. As such, strategies to maintain benefit after initial induction therapy are urgently needed. To fill this critical knowledge gap, and in response to PAR-25-032 NHLBI Clinical Trial Pilot Studies, we propose Preparing for Semaglutide Microdosing to Maintain Cardiovascular Health in People with HIV: The (pre-)SMASH CVD Trial to 1) determine preliminary effects of semaglutide microdosing in maintaining weight and cardiometabolic health in PWH following weight loss induction therapy; 2) assess the tolerability and acceptability of microdose semaglutide in PWH; 3) complete preparatory work critical to successful development of a larger, scientifically rigorous, Future randomized controlled trial (RCT). We will accomplish this in 3 aims: 1) To determine the rate of weight regain in PWH receiving semaglutide microdosing following induction therapy. Thirty adult PWH on suppressive antiretroviral therapy and with BMI 30 kg/m2 or 27 kg/m2 + 1 weight-related comorbidity will receive weight loss induction therapy with semaglutide 2.4 mg sc weekly for 12 weeks. Persons losing 5 lbs. (responders) will then be randomized 2:1 to maintenance with semaglutide 0.5 mg sc weekly (n=20) or no additional drug (n=10, the standard of care for “off-ramping”) for an additional 48 weeks. The primary outcome will be the difference in within-person weight regain between weeks 12 and 60. 2) To determine preliminary effects of semaglutide microdosing on additional endpoints. Some benefits of GLP-1RA, such as reduced CVD risk, are independent of weight and glucose lowering. We will characterize fat and lean mass quantity and distribution by DXA scan, muscle function by physical function testing, circulating cardiometabolic (glucose/lipid) and inflammatory biomarkers, blood pressure, ASCVD risk scores, semaglutide tolerability and acceptability and health self-perceptions. 3) To complete critical pre-trial work, including but not limited to development of the investigative teams, centralized imaging center, protocol and informed consents, supplemental and training materials, site training plans and database. These data are necessary for and will be sufficient to inform design of an efficient and high-impact Future RCT with cardiovascular endpoints. Development of a GLP-1RA microdosing strategy to sustain weight and cardiometabolic health in PWH following induction therapy is novel, significant and will undoubtedly provide valuable insights for intervention strategies in populations without HIV, adding substantial value to the field.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $255,458 )
2026	2026	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	7000 FANNIN ST FL 9	HOUSTON	TX	77030	HARRIS	USA	Cardiovascular Diseases Research	000	1	7/8/2026	NEW	$255,458
														Subtotal = $255,458

Grand Total All Awards = $255,458

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Preparing for Semaglutide Microdosing to Maintain Cardiovascular Health in People with HIV: The (pre-)SMASH CVD Trial

Award Number: R34HL182386

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/15/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer